Wuhan YZY Biopharma Co (HKSE:02496) Book Value per Share: HK$-0.30 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Wuhan YZY Biopharma Co Book Value per Share?

Wuhan YZY Biopharma Co HKSE:02496 Book Value per Share is HK$-0.30 as of Dec. 2025. The stock has 8 warning signs investors should review.

Wuhan YZY Biopharma Co's book value per share for the quarter that ended in Dec. 2025 was HK$-0.30.

During the past 12 months, Wuhan YZY Biopharma Co's average Book Value Per Share Growth Rate was -279.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Wuhan YZY Biopharma Co was -43.00% per year. The lowest was -43.00% per year. And the median was -43.00% per year.

Wuhan YZY Biopharma Co's current price is HK$3.30. Its book value per share for the quarter that ended in Dec. 2025 was HK$-0.30. Hence, today's PB Ratio of Wuhan YZY Biopharma Co is .

During the past 5 years, the highest P/B Ratio of Wuhan YZY Biopharma Co was 46.90. The lowest was 25.06. And the median was 35.12.

Wuhan YZY Biopharma Co  (HKSE:02496) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Wuhan YZY Biopharma Co Book Value per Share Related Terms

Wuhan YZY Biopharma Co Book Value per Share Historical Data

* Premium members only.

The historical data trend for Wuhan YZY Biopharma Co's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan YZY Biopharma Co Book Value per Share Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
0.91 0.90 0.72 0.17 -0.30

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Book Value per Share Get a 7-Day Free Trial 0.72 0.28 0.17 -0.16 -0.30

HKSE:02496 vs VRTX, REGN, RVMD: Book Value per Share Comparison

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's PB Ratio falls into.


Wuhan YZY Biopharma Co Book Value per Share Calculation

Wuhan YZY Biopharma Co's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-58.58-0.00)/193.85
=-0.30

Wuhan YZY Biopharma Co's Book Value Per Share for the quarter that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-58.58-0.00)/193.85
=-0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of HK$-0.30 mean?
Wuhan YZY Biopharma Co (HKSE:02496) has a Book Value per Share of HK$-0.30 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Wuhan YZY Biopharma Co and its competitors.
Is Wuhan YZY Biopharma Co's Book Value per Share too high?
Wuhan YZY Biopharma Co's current Book Value per Share is HK$-0.30.
How does Wuhan YZY Biopharma Co's Book Value per Share compare to VRTX and REGN?
Wuhan YZY Biopharma Co's Book Value per Share of HK$-0.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current Book Value per Share is HK$-0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current Book Value per Share of HK$-0.30. The current Book Value per Share is HK$-0.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current Book Value per Share is HK$-0.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan YZY Biopharma Co Business Description

Address No. 666 Gaoxin Road, Building C2-1, Optics Valley Bio-City, East Lake High Tech Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.